Periodic Evaluation of Anti-SARS-CoV-2 Antibody Levels and Determination of Surrogate Virus Neutralization in Healthcare Workers with COVID-19

2021 ◽  
Vol 55 (4) ◽  
pp. 507-518
Author(s):  
Yeşim Tuyji Tok ◽  
Mert Ahmet Kuşkucu ◽  
Devrim Sarıbal ◽  
Seda Salman Yılmaz ◽  
Okan Kadir Nohut ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Virus Neutralization ◽  
Periodic Evaluation ◽  
Antibody Levels

scholarly journals Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Stéphane Marot ◽  
◽  
Isabelle Malet ◽  
Valentin Leducq ◽  
Karen Zafilaza ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Disease Onset ◽  
Control Measures ◽  
Infection Prevention And Control ◽  
Rapid Decline ◽  
Prevention And Control Measures ◽  
Few Data ◽  
Antibody Levels ◽  
And Control

AbstractThere are only few data concerning persistence of neutralizing antibodies (NAbs) among SARS-CoV-2-infected healthcare workers (HCW). These individuals are particularly exposed to SARS-CoV-2 infection and at potential risk of reinfection. We followed 26 HCW with mild COVID-19 three weeks (D21), two months (M2) and three months (M3) after the onset of symptoms. All the HCW had anti-receptor binding domain (RBD) IgA at D21, decreasing to 38.5% at M3 (p < 0.0001). Concomitantly a significant decrease in NAb titers was observed between D21 and M2 (p = 0.03) and between D21 and M3 (p < 0.0001). Here, we report that SARS-CoV-2 can elicit a NAb response correlated with anti-RBD antibody levels. However, this neutralizing activity declines, and may even be lost, in association with a decrease in systemic IgA antibody levels, from two months after disease onset. This short-lasting humoral protection supports strong recommendations to maintain infection prevention and control measures in HCW, and suggests that periodic boosts of SARS-CoV-2 vaccination may be required.

A STUDY TO ASSESS THE SEROPREVALENCE OF HEPATITIS B AND ANTI HBS ANTIBODY LEVELS AMONGST HEALTH CARE WORKERS AND MEDICAL STUDENTS.

2021 ◽  
pp. 84-85
Author(s):  
Aditya Rana ◽  
Anuradha Sood
Keyword(s):  
Medical Students ◽  
Hepatitis B ◽  
Healthcare Workers ◽  
Base Material ◽  
Hepatitis B Vaccination ◽  
Continuous Exposure ◽  
Cross Sectional ◽  
Antibody Titres ◽  
Antibody Titers ◽  
Antibody Levels

Background: Hepatitis B(HBV) is a blood borne virus and it is one of the most important occupational hazards among healthcare workers (HCWs) & Medical students. This study aimed to measure the anti-HBs titres and to assess the seroprevalence of Hepatitis B in HCW and medical students. It was a prospective,descriptive and cross sectional hospital base Material and method: d study. Medical students and healthcare workers who had received all three doses of hepatitis B vaccination were included in the study. A total of 200 subjects , aged between 18 and Result: 62 years were taken. 182 were vaccinated and 18 were unvaccinated. 85 were males and 115 females. Seroprevalence of Hepatitis B was nil. Antibody titres were >100mIU/ml in 51.6% , 10-100mIU/ml in 16.4% & <10 mIU/ml in 31.8% respectively.Negative correlation of decreasing antibiotic titer and age was seen. HCW and medical students are at hi Conclusion: gher risk due to their continuous exposure to blood products. Vaccination should be compulsory to the HCW and medical workers in the institution as Hepatitis B is a preventable disease. Monitoring of antibody titers should be done from time to time to see waning off antibody titers after vaccination

‘Prostate Abscess' as the Initial Manifestation of Granulomatosis with Polyangiitis (Wegener's Granulomatosis)

2014 ◽  
Vol 96 (2) ◽  
pp. 244-246 ◽  
Author(s):  
Sotirios Tsiodras ◽  
Garyfalia Poulakou ◽  
Konstantinos Leventakos ◽  
Helen Panopoulou ◽  
Antonia Elezoglou ◽  
...  
Keyword(s):  
Wegener’S Granulomatosis ◽  
Granulomatosis With Polyangiitis ◽  
Systemic Disease ◽  
Wegener's Granulomatosis ◽  
Initial Manifestation ◽  
Postoperative Fever ◽  
Systemic Involvement ◽  
Left Pleural Effusion ◽  
Antibody Levels

Prostatic involvement in granulomatosis with polyangiitis (GWP), formerly known as Wegener's granulomatosis, is rare, mostly arising in the context of systemic involvement. Prostatic involvement as the first manifestation of this systemic disease is exceptionally rare. We hereby present the case of a 41-year-old male patient who underwent transurethral prostate resection for what was initially diagnosed as suppurative, focally necrotizing prostatitis. Prolonged postoperative fever that did not respond to various treatments, as well as the subsequent appearance of a left pleural effusion, a left upper pulmonary lobe lesion and cutaneous nodules, led to a reevaluation of histological slides which, along with the determination of serum c-ANCA/anti-PR3 antibody levels, established the diagnosis of GWP. Physicians, and especially urologists and infectious diseases specialists, should be aware of this rare association and consider GWP in the event of nonresolving prostatitis, especially when characteristic symptoms from other systems appear.

DETERMINATION OF MEASLES HEMAGGLUTINATION INHIBITING ANTIBODY LEVELS AMONG SCHOOL CHILDREN IN IBADAN, NIGERIA

2013 ◽  
Vol 34 (2) ◽  
pp. 208-217 ◽  
Author(s):  
Opeyemi T. Ogundiji ◽  
Iheanyi Omezuruike Okonko ◽  
Festus D. Adu
Keyword(s):  
School Children ◽  
Antibody Levels ◽  
Ibadan Nigeria

Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels

2013 ◽  
Vol 51 (12) ◽  
Author(s):  
Begoña Ruiz-Argüello ◽  
Ainhoa Ruiz del Agua ◽  
Nerea Torres ◽  
Alberto Monasterio ◽  
Antonio Martínez ◽  
...  
Keyword(s):  
Comparison Study ◽  
Antibody Levels

scholarly journals Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®)

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1063
Author(s):  
Jürgen Held ◽  
Jan Esse ◽  
Koray Tascilar ◽  
Philipp Steininger ◽  
Kilian Schober ◽  
...  
Keyword(s):  
Linear Regression ◽  
Regression Model ◽  
Linear Regression Model ◽  
Healthcare Workers ◽  
Model Performance ◽  
Neutralization Assay ◽  
Spike Protein ◽  
Igg Antibody ◽  
Boost Vaccination ◽  
Antibody Levels

mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as BNT162b2 (Comirnaty®), have proven to be highly immunogenic and efficient but also show marked reactogenicity, leading to adverse effects (AEs). Here, we analyzed whether the severity of AEs predicts the antibody response against the SARS-CoV-2 spike protein. Healthcare workers without prior SARS-CoV-2 infection, who received a prime-boost vaccination with BNT162b2, completed a standardized electronic questionnaire on the duration and severity of AEs. Serum specimens were collected two to four weeks after the boost vaccination and tested with the COVID-19 ELISA IgG (Vircell-IgG), the LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin-IgG) and the iFlash-2019-nCoV NAb surrogate neutralization assay (Yhlo-NAb). A penalized linear regression model fitted by machine learning was used to correlate AEs with antibody levels. Eighty subjects were enrolled in the study. Systemic, but not local, AEs occurred more frequently after the boost vaccination. Elevated SARS-CoV-2 IgG antibody levels were measured in 92.5% of subjects with Vircell-IgG and in all subjects with DiaSorin-IgG and Yhlo-NAb. Gender, age and BMI showed no association with the antibody levels or with the AEs. The linear regression model identified headache, malaise and nausea as AEs with the greatest variable importance for higher antibody levels (Vircell-IgG and DiaSorin-IgG). However, the model performance for predicting antibody levels from AEs was very low for Vircell-IgG (squared correlation coefficient r2 = 0.04) and DiaSorin-IgG (r2 = 0.06). AEs did not predict the surrogate neutralization (Yhlo-NAb) results. In conclusion, AEs correlate only weakly with the SARS-CoV-2 spike protein antibody levels after COVID-19 vaccination with BNT162b2 mRNA.

scholarly journals Significant reduction in humoral immunity among healthcare workers and nursing home residents 6 months after COVID-19 BNT162b2 mRNA vaccination

2021 ◽  
Author(s):  
David H. Canaday ◽  
Oladayo A. Oyebanji ◽  
Debbie Keresztesy ◽  
Michael Payne ◽  
Dennis Wilk ◽  
...  
Keyword(s):  
Nursing Home ◽  
Humoral Immunity ◽  
Healthcare Workers ◽  
Limit Of Detection ◽  
Nursing Home Residents ◽  
Good Health ◽  
Neutralization Assay ◽  
Vaccine Response ◽  
Post Vaccination ◽  
Antibody Levels

AbstractHigh COVID-19 mortality among nursing home (NH) residents led to their prioritization for SARS-CoV-2 vaccination; most NH residents received BNT162b2 mRNA vaccination under the Emergency Use Authorization due to first to market and its availability. With NH residents’ poor initial vaccine response, the rise of NH breakthrough infections and outbreaks, characterization of the durability of immunity to inform public health policy on the need for boosting is needed. We report on humoral immunity from 2 weeks to 6-months post-vaccination in 120 NH residents and 92 ambulatory healthcare worker controls with and without pre-vaccination SARS-CoV-2 infection. Anti-spike and anti-receptor binding domain (RBD) IgG, and serum neutralization titers, were assessed using a bead-based ELISA method and pseudovirus neutralization assay. Anti-spike, anti-RBD and neutralization levels dropped more than 84% over 6 months’ time in all groups irrespective of prior SARS-CoV-2 infection. At 6 months post-vaccine, 70% of the infection-naive NH residents had neutralization titers at or below the lower limit of detection compared to 16% at 2 weeks after full vaccination. These data demonstrate a significant reduction in levels of antibody in all groups. In particular, those infection-naive NH residents had lower initial post-vaccination humoral immunity immediately and exhibited the greatest declines 6 months later. Healthcare workers, given their younger age and relative good-health, achieved higher initial antibody levels and better maintained them, yet also experienced significant declines in humoral immunity. Based on the rapid spread of the delta variant and reports of vaccine breakthrough in NH and among younger community populations, boosting NH residents may be warranted.

scholarly journals Effect Monitoring and Insights from Vaccination program of Healthcare Workforce from a tertiary level hospital in India against SARS-CoV-2

2021 ◽  
Author(s):  
Rajat Ujjainia ◽  
Akansha Tyagi ◽  
Viren Sardana ◽  
Salwa Naushin ◽  
Nitin Bhatheja ◽  
...  
Keyword(s):  
Antibody Response ◽  
Neutralizing Antibodies ◽  
Healthcare Workers ◽  
Protein S ◽  
Maximum Increase ◽  
Post Vaccination ◽  
Neutralizing Activity ◽  
Effect Monitoring ◽  
Antibody Levels ◽  
Level Hospital

AbstractThe Oxford-Astra Zeneca COVID 19 vaccine (AZD1222 or ChAdOx1) is locally manufactured as Covishield by Serum Institute, Pune, India. In a group of 307 healthcare workers administered Covishield, we report measured antibody response to SARS-CoV-2 directed against the spike protein (S-antigen) at days 0, 7, 14, 28 and 45, with second dose on day 28 for all except 20 subjects who did not receive a second dose. In 129 subjects (42%) who had already developed antibodies to SARS-CoV-2 at day 0 (before immunization), it was observed that antibody response was significantly higher at each time point, with the maximum increase seen between days 0 and 7. The antibody levels and neutralizing activity in these subjects had peaked by day 28 and the second dose did not lead to further increase. Data from 9 subjects who were seropositive at baseline and received only one dose was similar to those who received both doses. In contrast the baseline sero-negative group (n=178) started developing antibody response only after 14 days or later. Administration of the second dose was associated with further increase in antibody levels at day 45 compared to day 28, with marked increase in neutralizing activity. In baseline seronegative subjects, who did not take the vaccine at day 28 (n=11), the antibody levels increased by about 2.5 folds between days 28 and 45, with minimal change in the neutralizing antibodies. In general, vaccination was well tolerated, and there were no group specific differences in post-vaccination symptomatology. Our data suggests that ChAdOx1 is highly immunogenic, particularly so where previous SARS CoV2 antibody-response is established. In such subjects, a single dose may be sufficient but in absence of such determination, both doses are required.

Sign in / Sign up

Export Citation Format

Share Document